Trials / Completed
CompletedNCT05363215
A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants
A Phase 1, Open-label, Parallel-group Study to Assess the Pharmacokinetics, Safety, and Tolerability of S-217622 in Participants With Mild, Moderate, and Severe Renal Impairment and Healthy Control Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Shionogi · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to measure the PK, safety, and tolerability of S-217622 in participants with mild, moderate, or severe renal impairment and in those with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S-217622 | Tablet for oral administration |
Timeline
- Start date
- 2022-08-10
- Primary completion
- 2023-04-12
- Completion
- 2023-04-12
- First posted
- 2022-05-05
- Last updated
- 2023-04-24
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05363215. Inclusion in this directory is not an endorsement.